A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis

Trial Profile

A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms JUNCTURE
  • Sponsors Novartis
  • Most Recent Events

    • 10 Apr 2017 Results (n=1709) of a pooled analysis from FIXTURE, FEATURE, ERASURE and JUNCTURE studies assessing the efficacy and safety of secukinumab in Hispanic and non-Hispanic patients, published in the Advances in Therapy.
    • 30 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 01 Dec 2016 Results of a pooled analysis assessing efficacy of secukinumab over 52 weeks from NCT01365455, NCT01358578, NCT01555125, and NCT01636687 studies published in the Dermatology and Therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top